The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study

被引：51

作者：

Soran, Atilla ^{[1
]}

Dogan, Lutfi ^{[2
]}

Isik, Arda ^{[3
]}

Ozbas, Serdar ^{[4
]}

Trabulus, Didem Can ^{[5
]}

Demirci, Umut ^{[6
]}

Karanlik, Hasan ^{[7
]}

Soyder, Aykut ^{[8
]}

Dag, Ahmet ^{[9
]}

Bilici, Ahmet ^{[10
]}

Dogan, Mutlu ^{[11
]}

Koksal, Hande ^{[12
]}

Sendur, Mehmet Ali Nahit ^{[13
]}

Gulcelik, Mehmet Ali ^{[14
]}

Maralcan, Gokturk ^{[15
]}

Cabioglu, Neslihan ^{[16
]}

Yeniay, Levent ^{[17
]}

Utkan, Zafer ^{[18
]}

Simsek, Turgay ^{[18
]}

Karadurmus, Nuri ^{[19
]}

Daglar, Gul ^{[4
]}

Yildiz, Birol ^{[19
]}

Uras, Cihan ^{[20
]}

Tukenmez, Mustafa ^{[16
]}

Yildirim, Ahmet ^{[11
]}

Kutun, Suat ^{[2
]}

Ozaslan, Cihangir ^{[2
]}

Karaman, Niyazi ^{[21
]}

Akcay, Mufide Nuran ^{[22
]}

Toktas, Osman ^{[23
]}

Sezgin, Efe ^{[24
]}

机构：

[1] Univ Pittsburgh Med Ctr, Div Surg Oncol, Magee Womens Hosp, Pittsburgh, PA 15213 USA

[2] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Surg Oncol, Ankara, Turkey

[3] Erzincan Binali Yildirim Univ, Dept Surg, Erzincan, Turkey

[4] Breast & Endocrine Surg, Ankara, Turkey

[5] Univ Hlth Sci, Istanbul Training & Res Hosp, Dept Surg, Istanbul, Turkey

[6] Univ Uskudar, Mem Ankara Hosp, Dept Med Oncol, Sch Med, Istanbul, Turkey

[7] Istanbul Univ, Surg Oncol Unit, Inst Oncol, Istanbul, Turkey

[8] Adnan Menderes Univ, Sch Med, Dept Surg, Aydin, Turkey

[9] Mersin Univ, Sch Med, Dept Surg, Mersin, Turkey

[10] Medipol Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey

[11] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[12] Univ Hlth Sci, Konya Training & Res Hosp, Dept Surg, Konya, Turkey

[13] Yildirim Beyazit Univ, Sch Med, Dept Med Oncol, Ankara, Turkey

[14] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Surg Oncol, Ankara, Turkey

[15] Sanko Univ, Sch Med, Dept Surg, Gaziantep, Turkey

[16] Istanbul Univ, Dept Surg, Sch Med, Istanbul, Turkey

[17] Ege Univ, Sch Med, Dept Surg, Izmir, Turkey

[18] Kocaeli Univ, Sch Med, Dept Surg, Izmit, Turkey

[19] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[20] Acibadem Univ, Dept Surg, Sch Med, Istanbul, Turkey

[21] Ankara Oncol Training & Res Hosp, Dept Surg, Ankara, Turkey

[22] Ataturk Univ, Sch Med, Dept Surg, Erzurum, Turkey

[23] Yuzuncu Yil Univ, Sch Med, Dept Surg, Van, Turkey

[24] Izmir Inst Technol, Fac Engn, Dept Food & Engn, Izmir, Turkey

来源：

ANNALS OF SURGICAL ONCOLOGY | 2021年 / 28卷 / 09期

关键词：

PRIMARY TUMOR; LOCOREGIONAL TREATMENT; SURGICAL RESECTION; SURVIVAL; IMPACT; METAANALYSIS; REMOVAL;

D O I：

10.1245/s10434-021-09621-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). Methods The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group). Results We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001). Conclusion In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.

引用

页码：5048 / 5057

页数：10

共 27 条

[1] Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes? [J].